drugset / Trial / NCT04838847
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The primary objective of this study is to evaluate the humoral immune response to CVnCoV in elderly adults aged ≥65 years and younger adults aged 18-45 years, 14 days after the second dose administration.
Timeline
- Start
- 2021-10-01
- Primary completion
- 2022-01
- Completion
- 2022-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZORECIMERAN | Messenger RNA (mRNA) | 12 ug | Intramuscular |